Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Robert J. Motzer, Scott S. Tykodi, Bernard Escudier, Stephane Oudard, Hans J. Hammers, David F. McDermott, Saby George, Daniel Castellano, Toni K. Choueiri, Ajjai Shivaram Alva, Martin Eduardo Richardet, Elizabeth R. Plimack, Sandy Srinivas, Giuseppe Procopio, Frede Donskov, Howard Gurney, Yoshihiko Tomita, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir
Institutions: Memorial Sloan Kettering Cancer Center, University of Washington, Fred Hutch Cancer Center, Institut Gustave Roussy, Hôpital Européen Georges-Pompidou, The University of Texas Southwestern Medical Center, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Roswell Park Comprehensive Cancer Center, Hospital Universitario 12 De Octubre, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, University of Michigan, Fox Chase Cancer Center, Stanford Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Aarhus University Hospital, Macquarie University, Niigata University, Bristol-Myers Squibb (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3007802343